Skip to main content
Clinical Trials/CTRI/2024/06/069512
CTRI/2024/06/069512Not yet recruitingPhase 2/3

clinical study on Virechana karma with Misraka sneha in the management of Amavata.

DrSindhoora V Prabhu1 site in 1 country30 target enrollmentStarted: May 7, 2024Last updated:
Conditions

Trial Snapshot

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
whether the given medicine is effective in causing proper purgation (samyak virikta lakshanas)

Study Overview

Brief Summary

**Name of the Department-**Department of Panchakarma

Name of the Student- Dr. Sindhoora V Prabhu

Name of the Guide- Dr. Lohith B A

**Title of the Study-**Clinical Study on Virechana Karma With Misraka Sneha In The Management Of Amavata

Virechana is a Karma, where doshas are expelled out of body through gudamarga. Misrakasneha is one of the formulation explained in gulma chikitsa adhyaya of Ashtanga Hridaya, where it has been used for Sramsana in gulma rogi. It contains Eranda taila, Ghrita and Ksheera along with pippali, amalaka, draksha and shyamadigana dravyas.Though it is mentioned in Gulma chikitsa, it is similar to amruta for all types of Vatavyadhi.

Misrakasneha is rarely used medicine for virechana when compared to other sneha yogas.Utility ofMisrakasneha is not explored much yet. Based on the ingredients it may be effective in minimal dosage to produce Samyak Virikta lakshanas as compared to other yogas.

Amavata is the disease affecting Asthi and Sandhis wherein Ama and Vata are the initiating factors in the pathogenesis.Being contradictory in nature poses difficulty in planning the line of treatment. Due to wide spectrum of disease ,much prevalence in the society the disease is being chosen for the study. In Amavata chikitsa Sutra , Virechana is also one of the treatment. Chakradatta has emphasized specially about virechana which we can understand by the simile of Eranda taila as Gajakesari

Taking the above background into consideration, it was thought worthwhile to evaluate the efficacy of M**israkasnehafor V**irechana in the management of Amavata.

Study Design

Study Type
Interventional
Allocation
Not Applicable
Masking
Not Applicable

Eligibility Criteria

Ages
20.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Participants full fill the diagnostic criteria aged between 20 to 60 years of either gender.
  • •Participants with lakshanas of amavata
  • •Participants indicated for virechana.
  • •Participants with diabetes mellitus and hypertension under control.
  • •Participants with madhyama kosta.

Exclusion Criteria

  • •Participants diagnosed with other inflammatory and degenerative joint diseases.
  • •Pregnant and Lactating woman.
  • •Participants with Amavata presenting with complication including joint deformities.
  • •Any other condition interfering the course of treatment.

Outcomes

Primary Outcomes

whether the given medicine is effective in causing proper purgation (samyak virikta lakshanas)

Time Frame: On the day of purgation

Secondary Outcomes

  • 1.RHEUMATOID FACTOR(2.C-REACTIVE PROTEIN)

Investigators

Sponsor
DrSindhoora V Prabhu
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials

Purgation with misraka sneha in treating... | Clinical Trial